■进行此荟萃分析以评估植入RV疫苗后5岁以下的中国儿童中轮状病毒(RV)的患病率和流行株。
■使用PubMed对2019年至2023年之间发表的针对5岁以下儿童的RV腹泻的研究进行了系统回顾,Embase,WebofScience,CNKI,万方和中国计量数据。我们综合了他们的发现,以使用固定效应或随机效应模型检查RV疫苗实施后RV的患病率和遗传多样性。
■17项研究符合本荟萃分析的纳入标准。RV的总体患病率为19.00%。感染率最高的是12-23个月的儿童(25.79%),其次是24-35个月(23.91%),和6-11个月(22.08%)。血清型G9成为最主要的RV基因型,占感染的85.48%,其次是G2(7.70%),八国集团(5.74%),G1(4.86%),和G3(3.21%)。最常见的P型是P型[8],占RV病例的64.02%。在G-P组合中,G9P[8]是最常见的,占RV感染的78.46%,由G8P[8](31.22%)和G3P[8](8.11%)接替。
■尽管在中国观察到血清型存在差异,G1,G2,G3,G8和G9血清型占大多数RV菌株。遗传多样性分析突出了RV基因型的动态性质,需要持续监测以监测毒株分布的变化并为未来的疫苗策略提供信息。
UNASSIGNED: This meta-analysis was performed to assess the prevalence and circulating strains of rotavirus (RV) among Chinese children under 5 years of age after the implantation of the RV vaccine.
UNASSIGNED: Studies published between 2019 and 2023, focused on RV-based diarrhea among children less than 5 years were systematically reviewed using PubMed, Embase, Web of Science, CNKI, Wanfang and SinoMed Data. We synthesized their findings to examine prevalence and genetic diversity of RV after the RV vaccine implementation using a fixed-effects or random-effects model.
UNASSIGNED: Seventeen studies met the inclusion criteria for this meta-analysis. The overall prevalence of RV was found to be 19.00%. The highest infection rate was noted in children aged 12-23months (25.79%), followed by those aged 24-35 months (23.91%), and 6-11 months (22.08%). The serotype G9 emerged as the most predominant RV genotype, accounting for 85.48% of infections, followed by G2 (7.70%), G8 (5.74%), G1 (4.86%), and G3 (3.21%). The most common P type was P[8], representing 64.02% of RV cases. Among G-P combinations, G9P[8] was the most frequent, responsible for 78.46% of RV infections, succeeded by G8P[8] (31.22%) and G3P[8] (8.11%).
UNASSIGNED: Despite the variation of serotypes observed in China, the G1, G2, G3, G8 and G9 serotypes accounted for most RV strains. The genetic diversity analysis highlights the dynamic nature of RV genotypes, necessitating ongoing surveillance to monitor changes in strain distribution and inform future vaccine strategies.